Summary
Months after cancer drug trial, Merus agrees to be bought at 41% premium
Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.81 per share a year ago.
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Merus N.V. (MRUS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Merus N.V. ever had a stock split?
Merus N.V. Profile
| Biotechnology Industry | Healthcare Sector | Sven Ante Lundberg CEO | NASDAQ (NMS) Exchange | N5749R100 CUSIP |
| NL Country | 260 Employees | - Last Dividend | - Last Split | 19 May 2016 IPO Date |
Overview
Merus N.V. is positioned at the forefront of immuno-oncology, dedicated to pioneering the development of innovative antibody therapeutics. Established in 2003 and based in Utrecht, the Netherlands, Merus is focused on advancing a portfolio of bispecific and trispecific antibody candidates through clinical trials. These revolutionary treatments are being explored for their potential in addressing a wide array of cancers, including metastatic breast cancer, castration-resistant prostate cancer, non-small cell lung cancer, and relapsed/refractory T cell lymphoma, among others. The company's approach is distinguished by collaborations with leading pharmaceutical entities such as Betta Pharmaceuticals, Incyte Corporation, and Gilead Sciences, Inc., aiming to harness the power of cutting-edge science in the fight against cancer.
Products and Services
- Zenocutuzumab (MCLA-128)
This bispecific antibody candidate is being investigated in phase 2 clinical trials for metastatic breast cancer and castration-resistant prostate cancer. Additionally, it is part of Phase 1/2 trials targeting solid tumors with Neuregulin 1. Its development showcases Merus N.V.'s commitment to addressing complex cancers with innovative therapeutic options.
- MCLA-158
Currently in phase I clinical trials, MCLA-158 is designed to target solid tumors. This bispecific antibody leverages a novel approach to bind to cancer cells, highlighting Merus's dedication to expanding its cancer treatment portfolio.
- MCLA-145
In phase 1 clinical trials, MCLA-145 represents a key part of Merus's pipeline. Developed in collaboration with Incyte Corporation, this product is exploring potential treatments for patients with solid tumors, underlining the company's strategy of partnership in innovation.
- MCLA-129
This candidate is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors. MCLA-129 is also being developed under a collaboration agreement with Betta Pharmaceuticals, showcasing Merus's collaborative approach towards accelerating the development of cancer therapies.
- ONO-4685
ONO-4685 is in a Phase 1 clinical trial aimed at treating patients with relapsed/refractory T cell lymphoma. This reflects Merus N.V.'s efforts to explore treatments for a broader range of cancers, including those with limited treatment options.
- Novel Antibody-based Trispecific T-cell Engagers
In partnership with Gilead Sciences, Inc., Merus is working on the discovery of trispecific T-cell engagers. This initiative illustrates the company's pioneering spirit in leveraging antibody technology to potentially revolutionize cancer immunotherapy.
Contact Information
